Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group

Author:

Mettmann Vanessa L.12ORCID,Baumhoer Daniel3,Bielack Stefan S.14ORCID,Blattmann Claudia1,Friedel Godehard5,von Kalle Thekla6,Kager Leo7,Kevric Matthias1,Nathrath Michaela89,Sorg Benjamin1,Dürken Matthias10,Hecker‐Nolting Stefanie1

Affiliation:

1. Klinikum Stuttgart ‐ Olgahospital, Stuttgart Cancer Centre, Paediatrics 5 (Oncology, Haematology, Immunology) Stuttgart Germany

2. Medical Faculty Heidelberg Heidelberg University Heidelberg Germany

3. Bone Tumour Reference Centre, Institute of Medical Genetics and Pathology University Hospital Basel and University of Basel Basel Switzerland

4. Department for Paediatric Haematology and Oncology University's Children's Hospital Muenster Muenster Germany

5. Department of Thoracic Surgery University of Tubingen, Faculty of Science Tubingen Germany

6. Klinikum Stuttgart ‐ Olgahospital, Stuttgart Cancer Centre Institute of Radiology Stuttgart Germany

7. St. Anna Kinderspital University Hospital for Paediatric and Adolescent Medicine of the Medical University, and St. Anna Children's Cancer Research Institute (CCRI) Vienna Austria

8. Department of Paediatrics and Children's Cancer Research Centre, Klinikum rechts der Isar Technical University of Munich, School of Medicine Munich Germany

9. Paediatric Haematology and Oncology, Klinikum Kassel Kassel Germany

10. Department of Paediatric Haematology and Oncology Mannheim University Hospital Mannheim Germany

Abstract

AbstractBackgroundTo evaluate patient and tumour characteristics, treatment and their impact on survival in patients with a solitary pulmonary metastasis at first relapse of high‐grade osteosarcoma.ProcedureTwo‐hundred and nineteen consecutive patients who had achieved a complete surgical remission and then developed a solitary pulmonary metastasis at first recurrence of high‐grade osteosarcoma were retrospectively reviewed.ResultsTwo hundred and three (94.9%) of 214 patients achieved a second complete remission. After a median time from initial diagnosis of osteosarcoma to first relapse of 2.3 years (range, 0.3–18.8 years), actuarial post‐relapse overall survival after 2 and 5 years was 72.0% and 51.2%. Post‐relapse event‐free survival was 39.1% and 31.1%. Median follow‐up time was 3.2 years (range, 0.1–29.4 years). A longer time until first relapse and diagnosis due to imaging were positive prognostic factors in uni‐ and multivariate analyses, as were a second complete surgical remission and, in regard to death, the absence of a subsequent relapse. The use of salvage chemotherapy and radiotherapy were not associated with patient outcomes, nor was the surgical approach (thoracoscopy vs. thoracotomy) nor the exploration (uni‐ vs. bilateral).ConclusionApproximately half of the patients who experience a solitary pulmonary relapse at first recurrence of osteosarcoma remain alive 5 years after this first relapse. Only one third will remain disease‐free. A complete surgical resection of the lesion is essential for long‐term survival while relapse chemotherapy does not seem to improve survival. Innovative therapies are required to improve outcomes.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference35 articles.

1. ErdmannFKP GrabowD SpixC.German Childhood Cancer Registry–Annual Report 2019 (1980–2018). Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz.2020https://www.kinderkrebsregister.de/typo3temp/secure_downloads/42507/0/1c5976c2ab8af5b6b388149df7182582a4cd6a39/Buch_DKKR_Jahresbericht_2019_komplett.pdf[accessed 17 May 23]

2. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

3. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group

5. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Oncology;Bone & Joint 360;2023-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3